Patent ID: 6518272
Filing Date: 2003-02-11
Classification: C07D

Abstract:
A method of treating one or more conditions modulated by serotonin 5-HT1A receptors in the central nervous system and in the body of a mammal comprising administering to a mammal having a condition modulated by serotonin 5-HT1A receptors a therapeutically effective amount of a compound according to the formula wherein:X is selected from the group consisting of; n is selected from the integers 1 through 5; R1 is C6-C10-aryl or mono or bicyclic heteroaryl having 5-10 atoms, 1 to 3 of which are heteroatoms selected independently from N, S or O, wherein the aryl or heteroaryl group is optionally substituted by F, Cl, Br, I, â€”OH, â€”NH2, CO2H, â€”CO2â€”C1-C6 alkyl, â€”CN, â€”NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perhaloalkyl, OR4, or C1-C6 perhaloalkyl, with a proviso that heteroaryl is not thiadiazole; R2 is selected from the group consisting of H and C1-C6 alkyl; R3 is selected from the group consisting of H, COR5, COOR5, and CONR5R6; R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl or mono or bicyclic heteroaryl as defined above, C7-C14 aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or mono or bicyclic heteroaryl group is as defined above and optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, â€”NH2, â€”NO2, â€”OH, alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perhaloalkyl, C1-C6 alkoxy, and C1-C6 perhaloalkoxy; R5 and R6 are selected independently from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together with the interposed nitrogen atom may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5 or R6 are C3-C6 cycloalkyl or C3-C6 cycloalkenyl, the cyclic group may optionally be substituted at the 1-position with a C1-C3 alkyl group; or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or both; with the proviso that when X is the condition treated is not anxiety or depression.